Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
987 questions in 78 reviews · Haematology
current versionsNo studies 256 · 25.9%Ungraded 64 · 6.5%Very low 207 · 21%Low 247 · 25%Moderate 163 · 16.5%High 50 · 5.1%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Yoga in addition to standard care vs standard care only Fatigue Scale from: 0 to 10. Higher scores indicate a higher level of fatigue · patients with haematological malignancies Yoga in addition to standard care for patients with haematological malignancies (2014) · Cochrane | MD 0 | NR | Very low |
Yoga in addition to standard care vs standard care only Anxiety Scale from: 20 to 80. Higher scores indicate higher levels of state anxiety · patients with haematological malignancies Yoga in addition to standard care for patients with haematological malignancies (2014) · Cochrane | MD 0.3 | NR | Very low |
Yoga in addition to standard care vs standard care only Depression Scale from: 0 to 60. Higher scores indicate more depressive symptoms · patients with haematological malignancies Yoga in addition to standard care for patients with haematological malignancies (2014) · Cochrane | no estimate extracted | NR | Very low |
Yoga in addition to standard care vs standard care only Quality of sleep Scale from: 0 to 21. Higher scores indicate a lower quality of sleep · patients with haematological malignancies Yoga in addition to standard care for patients with haematological malignancies (2014) · Cochrane | no estimate extracted | NR | Very low |
Yoga in addition to standard care vs standard care only Adverse events · patients with haematological malignancies Yoga in addition to standard care for patients with haematological malignancies (2014) · Cochrane | no estimate extracted | NR | No studies |
BMT vs PBSCT Mortality · participants with haematological malignancies Bone marrow versus peripheral blood allogeneic haematopoietic stem cell transplantation for haematological… (2014) · Cochrane | HR 1.07 [0.91, 1.25] | 6 studies · 1330 participants | High |
BMT vs PBSCT Progress, relapse or death · participants with haematological malignancies Bone marrow versus peripheral blood allogeneic haematopoietic stem cell transplantation for haematological… (2014) · Cochrane | HR 1.04 [0.89, 1.21] | 6 studies · 1225 participants | Moderate |
BMT vs PBSCT Non relapse or transplant related mortality · participants with haematological malignancies Bone marrow versus peripheral blood allogeneic haematopoietic stem cell transplantation for haematological… (2014) · Cochrane | HR 0.98 [0.76, 1.28] | 3 studies · 758 participants | High |
BMT vs PBSCT Extensive chronic GvHD · participants with haematological malignancies Bone marrow versus peripheral blood allogeneic haematopoietic stem cell transplantation for haematological… (2014) · Cochrane | HR 0.69 [0.54, 0.9] | 4 studies · 765 participants | Moderate |
BMT vs PBSCT Acute GvHD III to IV · participants with haematological malignancies Bone marrow versus peripheral blood allogeneic haematopoietic stem cell transplantation for haematological… (2014) · Cochrane | HR 0.75 [0.55, 1.02] | 3 studies · 925 participants | Moderate |
BMT vs PBSCT Chronic GvHD overall · participants with haematological malignancies Bone marrow versus peripheral blood allogeneic haematopoietic stem cell transplantation for haematological… (2014) · Cochrane | HR 0.72 [0.61, 0.85] | 4 studies · 1121 participants | Moderate |
BMT vs PBSCT Acute GvHD II to IV · participants with haematological malignancies Bone marrow versus peripheral blood allogeneic haematopoietic stem cell transplantation for haematological… (2014) · Cochrane | HR 1.03 [0.89, 1.21] | 6 studies · 1330 participants | Moderate |
Mycophenolate mofetil vs methotrexate Overall survival · people receiving allogeneic hematopoietic stem cell transplantation Mycophenolate mofetil versus methotrexate for prevention of graft‐versus‐host disease in people receiving… (2014) · Cochrane | HR 0.73 [0.45, 1.17] | 2 studies · 129 participants | Low |
Mycophenolate mofetil vs methotrexate Prevention of acute GVHD grade II to IV · people receiving allogeneic hematopoietic stem cell transplantation Mycophenolate mofetil versus methotrexate for prevention of graft‐versus‐host disease in people receiving… (2014) · Cochrane | RR 1.25 [0.75, 2.09] | 3 studies · 174 participants | Very low |
Mycophenolate mofetil vs methotrexate Incidence of relapse · people receiving allogeneic hematopoietic stem cell transplantation Mycophenolate mofetil versus methotrexate for prevention of graft‐versus‐host disease in people receiving… (2014) · Cochrane | RR 0.84 [0.52, 1.38] | 2 studies · 129 participants | Low |
Mycophenolate mofetil vs methotrexate Nonrelapse mortality · people receiving allogeneic hematopoietic stem cell transplantation Mycophenolate mofetil versus methotrexate for prevention of graft‐versus‐host disease in people receiving… (2014) · Cochrane | RR 1.21 [0.62, 2.36] | 1 study · 89 participants | Low |
Mycophenolate mofetil vs methotrexate Prevention of chronic GVHD · people receiving allogeneic hematopoietic stem cell transplantation Mycophenolate mofetil versus methotrexate for prevention of graft‐versus‐host disease in people receiving… (2014) · Cochrane | RR 0.92 [0.65, 1.3] | 2 studies · 129 participants | Low |
Mycophenolate mofetil vs methotrexate Incidence of severe mucositis · people receiving allogeneic hematopoietic stem cell transplantation Mycophenolate mofetil versus methotrexate for prevention of graft‐versus‐host disease in people receiving… (2014) · Cochrane | RR 0.48 [0.32, 0.73] | 3 studies · 174 participants | Low |
Mycophenolate mofetil vs methotrexate Use of total parenteral nutrition · people receiving allogeneic hematopoietic stem cell transplantation Mycophenolate mofetil versus methotrexate for prevention of graft‐versus‐host disease in people receiving… (2014) · Cochrane | RR 0.48 [0.26, 0.91] | 2 studies · 129 participants | Low |
Mycophenolate mofetil vs methotrexate Incidence of narcotic use for pain control · people receiving allogeneic hematopoietic stem cell transplantation Mycophenolate mofetil versus methotrexate for prevention of graft‐versus‐host disease in people receiving… (2014) · Cochrane | RR 0.76 [0.63, 0.91] | 2 studies · 129 participants | Low |
Eculizumab vs placebo Overall survival ‐ not measured · patients with paroxysmal nocturnal hemoglobinuria Eculizumab for treating patients with paroxysmal nocturnal hemoglobinuria (2014) · Cochrane | no estimate extracted | 1 study · 87 participants | Ungraded |
Eculizumab vs placebo All‐cause mortality · patients with paroxysmal nocturnal hemoglobinuria Eculizumab for treating patients with paroxysmal nocturnal hemoglobinuria (2014) · Cochrane | no estimate extracted | 1 study · 87 participants | Ungraded |
Eculizumab vs placebo Health‐related quality of life European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ‐C30). Scale from: 0 to 100 (a higher score means a better outcome) · patients with paroxysmal nocturnal hemoglobinuria Eculizumab for treating patients with paroxysmal nocturnal hemoglobinuria (2014) · Cochrane | no estimate extracted | 1 study · 87 participants | Low |
Eculizumab vs placebo Fatigue Functional Assessment of Chronic Illness Therapy‐Fatigue (FACIT‐Fatigue). Scale from: 0 to 52 (a higher score means a better outcome) · patients with paroxysmal nocturnal hemoglobinuria Eculizumab for treating patients with paroxysmal nocturnal hemoglobinuria (2014) · Cochrane | no estimate extracted | 1 study · 87 participants | Moderate |
Eculizumab vs placebo Adverse events (serious and nonserious) Medical Dictionary for Regulatory Activities (MedDRA) · patients with paroxysmal nocturnal hemoglobinuria Eculizumab for treating patients with paroxysmal nocturnal hemoglobinuria (2014) · Cochrane | RR 0.45 [0.15, 1.37] | 1 study · 87 participants | Low |
Eculizumab vs placebo Transfusion independence · patients with paroxysmal nocturnal hemoglobinuria Eculizumab for treating patients with paroxysmal nocturnal hemoglobinuria (2014) · Cochrane | RR 46.02 [2.88, 735.53] | 1 study · 87 participants | Moderate |
Eculizumab vs placebo Withdrawal for any reason · patients with paroxysmal nocturnal hemoglobinuria Eculizumab for treating patients with paroxysmal nocturnal hemoglobinuria (2014) · Cochrane | RR 0.2 [0.05, 0.88] | 1 study · 87 participants | Moderate |
First‐line allogeneic hematopoietic stem cell transplantation of HLA‐matched sibling donors vs first‐line ciclosporin and/or antithymocyte or antilymphocyte globulin Overall mortality · patients with acquired SAA First‐line allogeneic hematopoietic stem cell transplantation of HLA‐matched sibling donors compared with… (2013) · Cochrane | HR 0.95 [0.45, 1.91] | 3 studies · 203 participants | Low |
First‐line allogeneic hematopoietic stem cell transplantation of HLA‐matched sibling donors vs first‐line ciclosporin and/or antithymocyte or antilymphocyte globulin Treatment‐related mortality · patients with acquired SAA First‐line allogeneic hematopoietic stem cell transplantation of HLA‐matched sibling donors compared with… (2013) · Cochrane | no estimate extracted | 2 studies · 54 participants | Very low |
First‐line allogeneic hematopoietic stem cell transplantation of HLA‐matched sibling donors vs first‐line ciclosporin and/or antithymocyte or antilymphocyte globulin Health‐related quality of life · patients with acquired SAA First‐line allogeneic hematopoietic stem cell transplantation of HLA‐matched sibling donors compared with… (2013) · Cochrane | no estimate extracted | 0 studies · 0 participants | Ungraded |
First‐line allogeneic hematopoietic stem cell transplantation of HLA‐matched sibling donors vs first‐line ciclosporin and/or antithymocyte or antilymphocyte globulin Graft failure · patients with acquired SAA First‐line allogeneic hematopoietic stem cell transplantation of HLA‐matched sibling donors compared with… (2013) · Cochrane | no estimate extracted | 2 studies · 54 participants | Very low |
First‐line allogeneic hematopoietic stem cell transplantation of HLA‐matched sibling donors vs first‐line ciclosporin and/or antithymocyte or antilymphocyte globulin No response to IST · patients with acquired SAA First‐line allogeneic hematopoietic stem cell transplantation of HLA‐matched sibling donors compared with… (2013) · Cochrane | no estimate extracted | 2 studies · 35 participants | Very low |
First‐line allogeneic hematopoietic stem cell transplantation of HLA‐matched sibling donors vs first‐line ciclosporin and/or antithymocyte or antilymphocyte globulin Graft‐versus‐host disease · patients with acquired SAA First‐line allogeneic hematopoietic stem cell transplantation of HLA‐matched sibling donors compared with… (2013) · Cochrane | no estimate extracted | 2 studies · 52 participants | Very low |
First‐line allogeneic hematopoietic stem cell transplantation of HLA‐matched sibling donors vs first‐line ciclosporin and/or antithymocyte or antilymphocyte globulin Secondary clonal disease or malignancies · patients with acquired SAA First‐line allogeneic hematopoietic stem cell transplantation of HLA‐matched sibling donors compared with… (2013) · Cochrane | Peto OR 0.54 [0.07, 4] | 2 studies · 170 participants | Low |
Intervention NR Mortality for thrombotic events [ · patients with polycythaemia vera Antiplatelet drugs for polycythaemia vera and essential thrombocythaemia (2013) · Cochrane | OR 0.2 | 2 studies · 630 participants | Moderate |
Intervention NR Mortality for bleedings [ · patients with polycythaemia vera Antiplatelet drugs for polycythaemia vera and essential thrombocythaemia (2013) · Cochrane | no estimate extracted | 2 studies · 630 participants | Moderate |
Intervention NR All‐cause mortality [ · patients with polycythaemia vera Antiplatelet drugs for polycythaemia vera and essential thrombocythaemia (2013) · Cochrane | OR 0.46 | 2 studies · 630 participants | Moderate |
Intervention NR Major bleeding [ · patients with polycythaemia vera Antiplatelet drugs for polycythaemia vera and essential thrombocythaemia (2013) · Cochrane | OR 0.99 | 2 studies · 630 participants | Moderate |
Intervention NR Minor bleeding [ · patients with polycythaemia vera Antiplatelet drugs for polycythaemia vera and essential thrombocythaemia (2013) · Cochrane | OR 1.85 | 2 studies · 630 participants | Moderate |
ACR vs non‐ACR Overall survival number of dead patients · adults receiving treatment for follicular lymphoma Anthracycline‐containing regimens for treatment of follicular lymphoma in adults (2013) · Cochrane | HR 0.99 [0.77, 1.29] | 3 studies · 464 participants | Moderate |
ACR vs non‐ACR Mortality at 3 years · adults receiving treatment for follicular lymphoma Anthracycline‐containing regimens for treatment of follicular lymphoma in adults (2013) · Cochrane | RR 0.92 [0.67, 1.26] | 3 studies · 465 participants | Moderate |
ACR vs non‐ACR Overall response · adults receiving treatment for follicular lymphoma Anthracycline‐containing regimens for treatment of follicular lymphoma in adults (2013) · Cochrane | RR 1.06 [1, 1.12] | 3 studies · 622 participants | Moderate |
ACR vs non‐ACR Disease control number of patients with progression · adults receiving treatment for follicular lymphoma Anthracycline‐containing regimens for treatment of follicular lymphoma in adults (2013) · Cochrane | HR 0.65 [0.52, 0.81] | 4 studies · 759 participants | High |
ACR vs non‐ACR Progression/relapse at 3 years · adults receiving treatment for follicular lymphoma Anthracycline‐containing regimens for treatment of follicular lymphoma in adults (2013) · Cochrane | RR 0.73 [0.63, 0.85] | 4 studies · 724 participants | High |
ACR vs non‐ACR Neutropenia grade 3‐4 · adults receiving treatment for follicular lymphoma Anthracycline‐containing regimens for treatment of follicular lymphoma in adults (2013) · Cochrane | RR 1.94 [1.46, 2.56] | 2 studies · 533 participants | Very low |
ACR vs non‐ACR Cardiotoxicity** · adults receiving treatment for follicular lymphoma Anthracycline‐containing regimens for treatment of follicular lymphoma in adults (2013) · Cochrane | RR 4.55 [0.92, 22.49] | 3 studies · 1412 participants | Very low |
Intervention NR Mortality (after 3 years) · Patients with refractory/relapsed Hodgkin lymphoma High‐dose chemotherapy followed by autologous stem cell transplantation for patients with… (2013) · Cochrane | HR 0.67 [0.41, 1.07] | 2 studies · 157 participants | Moderate |
Intervention NR Relapse or death (at 3 years) · Patients with refractory/relapsed Hodgkin lymphoma High‐dose chemotherapy followed by autologous stem cell transplantation for patients with… (2013) · Cochrane | HR 0.55 [0.35, 0.86] | 2 studies · 157 participants | Moderate |
Intervention NR Treatment‐related mortality ‐ overall analysis (at 3 years) · Patients with refractory/relapsed Hodgkin lymphoma High‐dose chemotherapy followed by autologous stem cell transplantation for patients with… (2013) · Cochrane | RR 0.61 [0.16, 2.22] | 2 studies · 157 participants | Moderate |
Intervention NR Adverse events not estimable · Patients with refractory/relapsed Hodgkin lymphoma High‐dose chemotherapy followed by autologous stem cell transplantation for patients with… (2013) · Cochrane | no estimate extracted | 1 study · 100 participants | Ungraded |